Combination of ace inhibitor with thiaside-like diuretic as an independent strategy of improved prognosis in type 2 diabetes mcllitus. advance trial


Cite item

Full Text

Full Text

Комбинация ингибитора ангиотензинпревращающего фермента с тиазидоподобным диуретиком - самостоятельная стратегия улучшения прогноза при сахарном диабете 2-го типа: исследование advance. -
×

About the authors

V V Fomin

O M Eliseev

References

  1. Секция артериальной гипертонии ВНОК. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). М.; 2005.
  2. Franklin К., Goldberg R. J., Spencer F. et al. GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coronary Events. Arch. Intern. Med. 2004; 164: 1457-1463.
  3. Sowers J. R., Epstein M., Frohlich E. D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059.
  4. Staessen J. A., Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
  5. Tuomilehto J., Rastenyte D., Birkenhager W. H. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med. 1999; 340: 677-684.
  6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J. A. M. A. 2002; 288: 2981-2997.
  7. ADVANCE Collaborative Group. Study rationale and design of ADVANCE: action in diabetes and vascular disease preterax and diamicron MR controlled evaluation. Diabetologia 2001; 44: 1118-1120.
  8. ADVANCE Collaborative Group. Action in diabetes and vascular disease: patient recruitment and characteristics of the study population at baseline. Diabet. Med. 2005; 22: 882-888.
  9. Beltran A., McVeigh G., Morgan D. et al. Arterial compliance abnormalities in isolated systolic hypertension. Am. J. Hypertens. 2001; 14: 1007-1011.
  10. Бойцов С. А. Изучение патогенеза гипертонической болезни продолжается. Тер. арх. 2006; 9: 5-12.
  11. The CAFÉ Investigators. Differential impact of blood-pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation 2006; 113 (9): 1213-1225.
  12. Neal L., Greene E. L. Pathophysiology of chronic progressive renal disease in the African American patient with hypertension. Am. J. Med. Sci. 2002; 323: 72-77.
  13. Baigent C, Keech A., Kearney P. M. et al. Cholesterol Treatment Trialists' (CTT) Collaborators; efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278.
  14. Беленков Ю. H., Мареев В. Ю. Как мы лечим больных с сердечно-сосудистыми заболеваниями в реальной клинической практике. Тер. арх. 2003; 8: 5-11.
  15. Dzau V. J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047-1052.
  16. Bottinger E. P., Bitzer M. TGF-Β signaling in renal disease. J. Am. Soc. Nephrol. 2002; 13: 2600-2610.
  17. Folii F., Saad M. J., Velloso L. et al. Crosstalk between insulin and angiotensin II signaling systems. Exp. Clin. Endocrinol. Diabet. 1999; 107: 133-139.
  18. Cottone S., Vadala A., Mangano M. T. et al. Endothelium-derived factors in microalbuminuric and nonmicroalbuminuric essential hypertensives. Am. J. Hypertens. 2000; 13: 172-176.
  19. De Jong P. E., Brenner В. M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004; 66: 2109-2118.
  20. Stehouwer C. D. Endothelial dysfunction in diabetic nephropathy: state of art and potential significance for non-diabetic renal disease. Nephrol. Dial. Transplant. 2004; 19: 778-781.
  21. Шестакова M. В., Ярек-Мартынова И. Р., Иванишина Н. С. и др. Кардиоренальный синдром при сахарном диабете 1 типа: роль дисфункции эндотелия. Кардиология 2005; 6: 35-41.
  22. Gasic S., Wagner О. F., Fasching P. et al. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am. J. Hypertens. 1999; 12 (2, pt 1): 217-222.
  23. Шестакова M. В. Нефропротекция: роль артериального давления в прогрессировании патологии почек. Зависит ли нефропротективный эффект от выбора антигипертензивного препарата? Тер. арх. 2001; 6: 64-66.
  24. Gertsein Н. С., Bosch J., Pogue J. et al. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes: the MICRO-HOPE study. Diabet. Care 1996: 19: 1225-1228.
  25. The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
  26. Чазова И. E., Ратова Л. Г. Комбинированная терапия артериальной гипертонии. Сердце 2005; 4 (3): 120-126.
  27. Zillich A. G., Gard J., Basu S. et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48 (2): 219-224.
  28. Чазова И. E., Мычка В. Б. Окончательные результаты программы МИНОТАВР (пациенты с Метаболическим сИН-дрОмом - эффективность и переносимость Арифона ретард В лечении артериальной гипертонии). Consilium Medicum 2006; 8 (11): 11-15.
  29. Mogensen С. Е., Viberti G., Halimi S. et al. Effect of lowdose perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-1071.
  30. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840.
  31. Strandberg Т. E., Pyorala K., Cook T. J. et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364: 771-777.
  32. Perry H. M. Jr., Davis B. R., Price T. R. et al. Effect of treating isolated systolic hypertension on the risk of developing warious types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). J. A. M. A. 2000; 284: 465-471.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2008 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies